The results demonstrated an upregulation of both RIG-I and MHC-I in tumor tissues following intratumoral injection of isiBCL-2 (Fig. 7A–B), along with elevated levels of IFN-β and CXCL10 (Fig. 7C–D). Here, CXCL10 is linked to neoplasm.